Literature DB >> 11202205

Growth and hormone deficiency and peak bone mass.

R Bouillon1, A Prodonova.   

Abstract

In order to define the relationship between growth hormone (GH) and peak bone mass, and the importance of the role played by GH in reaching optimal peak bone mass, several questions, discussed in this article, have first to be answered. Although the answers to some of these questions are already becoming apparent, some await the findings of further research. It is doubtful whether the results of these studies, which by definition should be long-term because of the long lag between the end of linear growth and the attainment of peak bone mass, will soon be available. In the absence of evidence-based medicine one can, however, conclude that long-term GH replacement therapy for GH deficiency in adults has no deleterious effects on bone. Indeed, despite an increase in bone turnover and an increase in remodeling space, bone mineral density and bone mineral content have been shown to increase slowly over time and to the same degree in both controlled and uncontrolled studies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11202205     DOI: 10.1515/jpem-2000-s604

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  11 in total

Review 1.  Indications and strategies for continuing GH treatment during transition from late adolescence to early adulthood in patients with GH deficiency: the impact on bone mass.

Authors:  G Saggese; G I Baroncelli; T Vanacore; L Fiore; S Ruggieri; G Federico
Journal:  J Endocrinol Invest       Date:  2004-06       Impact factor: 4.256

Review 2.  Growth hormone therapy for people with thalassaemia.

Authors:  Chin Fang Ngim; Nai Ming Lai; Janet Yh Hong; Shir Ley Tan; Amutha Ramadas; Premala Muthukumarasamy; Meow-Keong Thong
Journal:  Cochrane Database Syst Rev       Date:  2017-09-18

3.  Growth hormone therapy for people with thalassaemia.

Authors:  Chin Fang Ngim; Nai Ming Lai; Janet Yh Hong; Shir Ley Tan; Amutha Ramadas; Premala Muthukumarasamy; Meow-Keong Thong
Journal:  Cochrane Database Syst Rev       Date:  2020-05-28

4.  Effects of body composition, leptin, and adiponectin on bone mineral density in prepubertal girls.

Authors:  Young Jun Rhie; Kee Hyoung Lee; So Chung Chung; Ho Seong Kim; Duk Hee Kim
Journal:  J Korean Med Sci       Date:  2010-07-21       Impact factor: 2.153

5.  Evidence that sensitivity to growth hormone (GH) is growth period and tissue type dependent: studies in GH-deficient lit/lit mice.

Authors:  Yuji Kasukawa; David J Baylink; Rongqing Guo; Subburaman Mohan
Journal:  Endocrinology       Date:  2003-09       Impact factor: 4.736

Review 6.  Skeletal effects of growth hormone and insulin-like growth factor-I therapy.

Authors:  Richard C Lindsey; Subburaman Mohan
Journal:  Mol Cell Endocrinol       Date:  2015-09-25       Impact factor: 4.102

7.  Effect of body composition on bone mineral density in Moroccan patients with juvenile idiopathic arthritis.

Authors:  Dalal El Badri; Samira Rostom; Ilham Bouaddi; Asmae Hassani; Bouchra Chkirate; Bouchra Amine; Najia Hajjaj-Hassouni
Journal:  Pan Afr Med J       Date:  2014-02-18

Review 8.  Effect of GH/IGF-1 on Bone Metabolism and Osteoporsosis.

Authors:  Vittorio Locatelli; Vittorio E Bianchi
Journal:  Int J Endocrinol       Date:  2014-07-23       Impact factor: 3.257

Review 9.  Clinical, Diagnostic, and Therapeutic Aspects of Growth Hormone Deficiency During the Transition Period: Review of the Literature.

Authors:  Matteo Spaziani; Chiara Tarantino; Natascia Tahani; Daniele Gianfrilli; Emilia Sbardella; Andrea M Isidori; Andrea Lenzi; Antonio F Radicioni
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-24       Impact factor: 5.555

Review 10.  Long-term Consequences of Traumatic Brain Injury in Bone Metabolism.

Authors:  Nikita M Bajwa; Chandrasekhar Kesavan; Subburaman Mohan
Journal:  Front Neurol       Date:  2018-03-05       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.